I just thought that was the best thing for me to do at this point’
Exploring patient experiences with depot buprenorphine and their motivations to discontinue
Dados Bibliográficos
| ID | 14905934 |
|---|---|
| Autores | Clay (0000-0001-6676-7608, UNSW Sydney, autor correspondente), Carla Treloar (0000-0002-8230-0386, UNSW Sydney), Louisa Degenhardt (0000-0002-8513-2218, UNSW Sydney), J Grebely (0000-0002-1833-2017, UNSW Sydney), Michael Christmass (0000-0001-9782-1849), Christopher M Gough (0000-0002-1227-7731), Chris Gough, Jeremy Hayllar (0000-0003-3065-7591, Metro South Health), Mike McDonough (0000-0002-6627-9345, Alcohol and Drug Foundation), C R Henderson (0000-0001-7264-2676, National Association of People with HIV Australia), Charles Henderson (0000-0003-0334-6739), Sione Crawford, Michael Farrell (0000-0002-0634-9719, UNSW Sydney), April D Marshall (0000-0001-7476-7894, UNSW Sydney) |
| Ano | 2023 |
| Volume | 115 |
| Páginas | 104002 |
| Data de publicação | 2023-05-01 |
| Peer Reviewed | Sim |
| Open Access | Sim |
| Tipo | ARTICLE |
| Periódico | International Journal of Drug Policy (JOURNAL) |
| Identificadores do periódico | ISSN: 0955-3959 • E-ISSN: 1873-4758 |
| Editora | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.drugpo.2023.104002 |
| PMID | 37003194 |
| OpenAlex | W4361256169 |
| Idioma | EN |
| Citações recebidas | 12 |
| Referências citadas | 43 |
Depot buprenorphine remains a promising treatment for OUD and offers potential to improve treatment adherence. Instances of restricted OAT choice and consumer concerns regarding a lack of agency must be addressed in order to enhance therapeutic relationships. Clinicians and other healthcare workers in this field also need greater access to information about depot buprenorphine to better address issues patients face during treatment. More research is required to understand patient and treatment choice given the options of these new treatment formulations
Buprenorphine · Depot · Family medicine · Feeling · Opioid · Opioid use disorder · Psychiatry · HIV, Drug Use, Sexual Risk · Medicine · Opioid Use Disorder Treatment · Psychology · Social Psychology · Substance Abuse Treatment and Outcomes · Internal Medicine
Reasons for Discontinuation and Associated Factors in Opioid Agonist Treatment
Patient satisfaction with long-acting injectable buprenorphine
Reported patient experiences of extended-release buprenorphine for opioid dependence
Making long‐acting treatment work
Factors Associated With Preferences for Opioid Agonist Therapies Among People Dependent on Opioids
Experiences of People Who Discontinue Long‐Acting Injectable Buprenorphine Treatment Recently Released From Prison in New South Wales, Australia
Initiation, retention, and discontinuation of extended-release buprenorphine (BUP-XR) for opioid dependence
Matters-of-concern’ associated with discontinuation of long-acting injectable buprenorphine
The dynamics of more-than-human care in depot buprenorphine treatment
The ‘knowing’ body in the becoming of buprenorphine depot treatment
Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022
Regimes of Drug Desires
Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups
Global patterns of opioid use and dependence
Medical homelessness and candidacy
Spoiled identity’ in hepatitis C infection
Substance Use Stigma, Primary Care, and the New York State Prescription Drug Monitoring Program
Peer to peer communication about hepatitis C treatment amongst people who inject drugs
Like being put on an ice floe and shoved away”
The politics of providing opioid pharmacotherapy
Can a new formulation of opiate agonist treatment alter stigma
Conceptualising access in the direct-acting antiviral era
Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden
Using thematic analysis in psychology
Intervention stigma
Qualitative study of candidacy and access to secondary mental health services during the Covid-19 pandemic
Good' patient/'bad' patient
| Obras citantes distintas | 12 |
|---|---|
| Citações por ano | 6 |
| Intervalo de citações | 2024 - 2026 (3) |
| Velocidade de citação | current |
| Altamente citado | Não |
| Tipos de citação | Neutras: 12 |